TABLE 2.
Univariate analysis for prior antibiotic exposure and invasive procedures among patients with CR KPC-KP and CS KPC-KP isolates
| Variable | No. (%) of patients |
P value | Mean duration of indicated exposure or procedure ± SD (days) |
P value | ||
|---|---|---|---|---|---|---|
| CR KPC-KP | CS KPC-KP | CR KPC-KP | CS KPC-KP | |||
| Prior antibiotic exposure | ||||||
| 3rd- and 4th-generation cephalosporins | 5 (38.5) | 14 (35.9) | 1 | 6.4 ± 3.4 | 9.7 ± 5 | 0.194 |
| β-Lactam/β-lactamase inhibitor combinations | 6 (46.2) | 27 (69.2) | 0.187 | 18.7 ± 6.5 | 10.5 ± 5.2 | 0.002 |
| Aminoglycosides | 5 (38.5) | 11 (28.2) | 0.506 | 12.2 ± 7 | 8.6 ± 4.8 | 0.243 |
| Quinolones | 7 (53.8) | 26 (66.7) | 0.51 | 13.7 ± 8.2 | 9.6 ± 5.3 | 0.116 |
| Carbapenems | 5 (38.5) | 9 (23.1) | 0.3 | 18.4 ± 13.4 | 12.2 ± 9.3 | 0.327 |
| Colistin | 4 (30.8) | 8 (20.5) | 0.466 | 20.5 ± 13 | 15.1 ± 7.2 | 0.369 |
| Tigecycline | 3 (23.1) | 6 (15.4) | 0.674 | 15.7 ± 11.5 | 15.0 ± 4.0 | 0.897 |
| Glycopeptides | 7 (53.8) | 13 (33.3) | 0.208 | 13.4 ± 11.1 | 14.5 ± 5.5 | 0.766 |
| Linezolid | 4 (30.8) | 6 (15.4) | 0.244 | 14.0 ± 8.3 | 11.0 ± 7.4 | 0.564 |
| Antifungals | 4 (30.8) | 9 (23.1) | 0.714 | 27.8 ± 22.0 | 11.6 ± 9.0 | 0.077 |
| Invasive procedures | ||||||
| Mechanical ventilation | 9 (69.2) | 26 (66.7) | 1 | 21 ± 15.6 | 14.4 ± 7.9 | 0.105 |
| Central line catheter | 13 (100) | 30 (76.9) | 0.091 | 20.2 ± 21.0 | 17.0 ± 11.4 | 0.517 |
| Urinary catheter | 13 (100) | 37 (94.9) | 1 | 20.5 ± 20.8 | 15.4 ± 11.8 | 0.282 |
| Nasogastric tube | 11 (84.6) | 30 (76.9) | 0.709 | |||
| Foreign materiala | 5 (38.5) | 9 (23.1) | 0.3 | |||
| Surgical operations after admission | 3 (23.1) | 10 (25.6) | 1 | |||
a
Foreign material included prosthetic valves, orthopedic devices, vascular and biliary stents, and pacemakers.